SHR0302
Drug timelines are a Plus or Pro feature.
13 regulatory and trial events tracked for SHR0302, covering 2016-01-26 to 2025-04-13. Get the full timeline:
Most recent: Clinical Trial Update: SHR0302 Combined With PD-1/PD-L1 Inhibition for Treatment naïve or Acquired Resistant to Immunology NSCLC [Phase 2]